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Abstract: The treatment of myocardial infarction is a major challenge in medicine due 
to the inability of heart tissue to regenerate. Direct reprogramming of endogenous cardiac 
fibroblasts into functional cardiomyocytes via the delivery of transcription factor mRNAs has 
the potential to regenerate cardiac tissue and to treat heart failure. Even though mRNA delivery 
to cardiac fibroblasts has the therapeutic potential, mRNA transfection in cardiac fibroblasts 
has been challenging. Herein, we develop an efficient mRNA transfection in cultured mouse 
cardiac fibroblasts via a polyarginine-fused heart-targeting peptide and lipofectamine complex, 
termed C-Lipo and demonstrate the partial direct reprogramming of cardiac fibroblasts towards 
cardiomyocyte cells. C-Lipo enabled the mRNA-induced direct cardiac reprogramming due to 
its efficient transfection with low toxicity, which allowed for multiple transfections of Gata4, 
Mef2c, and Tbx5 (GMT) mRNAs for a period of 2 weeks. The induced cardiomyocyte-like 
cells had α-MHC promoter-driven GFP expression and striated cardiac muscle structure from 
α-actinin immunohistochemistry. GMT mRNA transfection of cultured mouse cardiac fibro-
blasts via C-Lipo significantly increased expression of the cardiomyocyte marker genes, Actc1, 
Actn2, Gja1, Hand2, and Tnnt2, after 2 weeks of transfection. Moreover, this study provides 
the first direct evidence that the stoichiometry of the GMT reprogramming factors influence 
the expression of cardiomyocyte marker genes. Our results demonstrate that mRNA delivery 
is a potential approach for cardiomyocyte generation.
Keywords: direct cardiac reprogramming, cardiac fibroblast transfection, mRNA transfection, 
cardiac regeneration
Introduction
Myocardial infarction is a major cause of death in the world. An attractive therapy 
for myocardial infarction is to reprogram endogenous fibroblasts into cardiomyocytes 
in vivo and induce de novo cardiac regeneration.1,2 Significant progress has been 
made towards understanding the factors needed for direct reprogramming of cardiac 
cells. Ieda et al demonstrated that the overexpression of three cardiac transcription 
factors, Gata4, Mef2c, and Tbx5 (GMT), in mouse cardiac and tail-tip fibroblasts was 
sufficient to generate cardiomyocyte-like cells.2 In addition, retroviral transfection of 
cardiac fibroblasts in vivo with GMT induced direct reprogramming of those cells 
into functional cardiomyocytes, and also improved cardiac function in coronary 
artery–ligated mice.1,3 However, despite these promising studies, the translation of 
direct reprogramming by transcription factors has been hampered by safety concerns 
regarding the usage of retroviruses and lentiviruses, which have multiple disadvantages 
including immunogenicity, insertional mutagenesis, and tumorigenicity.4–7 
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The development of nonviral methods to perform 
direct reprogramming is a key step in enabling the clinical 
applications of this therapeutic approach; hence, there 
is a great interest in achieving this. Nonviral methods to 
reprogram fibroblasts into pluripotent stem cells have been 
developed using plasmids,8 mRNAs,4,9,10 and proteins.5,11 
In addition, the recent success of direct neuronal reprogram-
ming using plasmids demonstrates the potential of nonviral 
methods for direct reprogramming.6 Although nonviral 
methods have shown great promise for direct reprogramming, 
a general and versatile nonviral method for inducing direct 
reprogramming still needs to be developed.
mRNA delivery has great potential for direct reprogram-
ming and has several advantages over plasmid-based gene 
delivery.4,10 First, mRNA does not contain viral or bacterial 
promoter sequences that can induce innate immune responses.12 
Therefore, multiple mRNA transfections can be performed on 
mammalian cells. Second, mRNA transfection is more effective 
than DNA transfection on primary cells because it is not depen-
dent on nuclear delivery.13 Third, mRNA transfection can be 
used to identify the optimal ratio of transcription factors needed 
to generate mature and functioning cardiomyocytes. mRNA 
delivery allows for a fine control of transcription factor expres-
sion levels and a stoichiometric analysis explaining the effects 
of transcription factor levels on reprogramming, both insights 
that are not possible with viral vectors or plasmids.3,14 
Despite the great potential of mRNA transfection for 
direct reprogramming, current methods for delivering mRNA 
lack the efficiency or biocompatibility that are necessary 
for direct reprogramming applications. Traditional mRNA 
transfection methods have low efficiency and high toxicity for 
primary cardiac cells.15,16 In addition, the toxicity of transfec-
tion reagents is a critical issue for cellular reprogramming 
because reprogramming requires multiple transfections over 
a period of weeks.4,17 
In this report, we present the demonstration of mRNA-
induced cardiomyocyte-like gene expression in cardiac 
fibroblasts that were transfected with cardiac reprogramming 
factors in a new mRNA transfection system, termed C-Lipo, 
composed of a heart-targeting peptide (CRPPR-R9) and 
lipofectamine. CRPPR-R9 includes three parts: a CRPPR 
heart-targeting sequence, a four-glycine linker sequence, 
and a nine-arginine sequence (Figure 1). CRPPR is a heart-
targeting peptide sequence discovered by phage display, 
which has been shown to localize in the heart tissue of mice 
after intravenous injection.18,19 CRPPR-R9 is designed to 
electrostatically interact with negatively charged mRNA 
due to its nine positively charged arginine residues, and 
then trigger endocytosis of the complexed mRNA in cardiac 
fibroblasts. We show here that cardiac fibroblasts can be par-
tially reprogrammed towards cardiomyocyte-like cells via a 
daily transfection of GMT mRNAs using the C-Lipo system. 
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Figure 1 CRPPR-R9/lipofectamine/mRNA complex can deliver GMT mRNAs to cardiac fibroblasts and induct direct reprogramming towards cardiomyocyte-like cells.
Notes: C-Lipo composed of a heart-targeting peptide (CRPPR-R9) and lipofectamine facilitates mRNA delivery in cardiac fibroblasts. GMT mRNA transfection induces 
partial direct reprogramming of cardiac fibroblasts towards cardiomyocytes.
Abbreviation: GMT, Gata4, Mef2c, and Tbx5.
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The induced cardiomyocytes had striated α-actinin structure 
and expressed six characteristic markers of cardiomyocytes: 
α-MHC, Actc1, Actn2, Gja1, Hand2, and Tnnt2. 
Experimental section
Materials
pcDNA™6/V5-His B, Iscove’s Modified Dulbecco’s 
Medium (IMDM), Dulbecco’s Modified Eagle’s Medium 
(DMEM), fetal bovine serum (FBS), non-essential amino 
acids (NEAA), sodium pyruvate, GlutaMax, penicillin-
streptomycin, medium M199, OptiMEM I reduced-serum 
medium, lipofectamine 2000, Ulysis Alexa Fluor 594 nucleic 
acid labeling kit, 4′,6-diamidino-2-phenylindole (DAPI) for 
nucleus staining, and lipofectamine RNAiMax were pur-
chased from Thermo Fisher Scientific (Waltham, MA, USA). 
NEB 5-alpha competent Escherichia coli and Antarctic phos-
phatase were obtained from New England Biolabs (Ipswich, 
MA, USA). 3′-O-Me-m7G(5′)ppp(5′)G RNA cap analog, 
5-methylcytidine-5′-triphosphate (Me-CTP), pseudouridine-
5′-triphosphate (Pseudo-UTP), and enhanced green fluores-
cence protein (eGFP) mRNA were purchased from TriLink 
Biotechnologies (San Diego, CA, USA). Gelatin 0.1% solu-
tion and branched polyethylenimine (bPEI, 10 kDa) were 
purchased from Sigma-Aldrich Co. (St Louis, MO, USA). 
CRPPR-R9 (CRPPRGGGGRRRRRRRRR) and its control 
sequence, CRRPP-R9 (CRRPPGGGGRRRRRRRRR), were 
synthesized by Peptide 2.0 (Chantilly, VA, USA). Plasmid 
Midi Kit and QIAquick spin columns were purchased from 
Qiagen NV (Venlo, the Netherlands). Stemfect was obtained 
from Stemgent (Cambridge, MA, USA). TransIT-X2 and 
TransIT-mRNA were purchased from Mirus Bio LLC 
(Madison, WI, USA). Micro Bio-Spin P-6 column, Aurum 
Total RNA Mini kit, iScript cDNA synthesis kit, and SsoAd-
vanced Universal SYBR Green Supermix were obtained from 
Bio-Rad Laboratories Inc. (Hercules, CA, USA). 
Cardiac fibroblast isolation and culture
Neonatal cardiac fibroblasts were isolated as previously 
described following a conventional neonatal cardiac fibro-
blast isolation method.20 GFP-negative cardiac fibroblasts 
from genetically modified neonatal mice that express GFP 
by the α-MHC promoter (α-MHC-GFP) were sorted from 
migrated cells using MoFlo fluorescence-activated cell 
sorting (FACS; Beckman Coulter, Brea, CA, USA). GFP-/
Thy1+ cells were sorted and cultured for direct cardiac 
reprogramming experiments.20 Growth culture media was 
IMDM containing 20% FBS, 1% NEAA, 1% sodium 
pyruvate, 1% GlutaMAX, and 5% penicillin–streptomycin. 
Fresh cardiac fibroblasts, within 7 days from the isolation, 
were used for experiments. Cardiomyocyte medium that was 
given to cardiac fibroblasts after transfection was composed 
of DMEM and M199, 10% FBS, 1% NEAA, 1% sodium 
pyruvate, and 1% GlutaMAX. All cells were cultured at 
37°C and 5% CO
2
.
Primary cardiac fibroblast transfection 
with conventional transfection reagents
We tested various commercial transfection reagents including 
lipofectamine 2000, lipofectamine RNAiMAX, Stemfect, 
TransIT-X2, TransIT-mRNA (Mirus Bio LLC), and also 
polycationic polymers such as bPEI and PEG-polylysine 
(22 ethylene glycol units, 50 lysine units; Alamanda Poly-
mers Inc., Huntsville, AL, USA). Transfection was optimized 
by standard procedures or the manufacturer’s protocol. eGFP 
mRNA transfection was conducted overnight, washed with 
phosphate buffered saline (PBS), and observed with a fluo-
rescence microscope. eGFP-expressing cells with optimized 
transfection conditions were analyzed using flow cytometry 
(Guava easyCyte; EMD Millipore, Billerica, MA, USA).
cellular uptake of alexa594-mrNa via 
CRPPR-R9 in cardiac fibroblasts
Alexa594 labeling was conducted on 10 µg of eGFP 
mRNA with Ulysis Alexa Fluor 594 nucleic acid labeling 
kit (Thermo Fisher Scientific) following the manufacturer’s 
manual. Excess unreacted dyes were removed using a Micro 
Bio-Spin P-6 column (Bio-rad Laboratories Inc.). Cardiac 
fibroblasts (2×104 cells/well) were cultured on Millicell EZ 
slide (EMD Millipore) overnight. The Alexa594-labeled 
mRNA (500 ng/µL, 1 µL) was prepared with CRPPR-R9 
(PBS, 1 µg/µL, 3.8 µL) at a molar charge ratio of 20 in 
OptiMEM. The cardiac fibroblasts were transfected with 
mRNA/CRPPR-R9 complex: Alexa594-labeled mRNA 
(500 ng), CRPPR-R9 (3.8 µg), and only Alexa594-labeled 
mRNA control (500 ng). After 30 minutes incubation, the 
culture medium was removed and cells were washed with 
PBS three times. Cardiac fibroblasts were fixed in 4% para-
formaldehyde (Santa Cruz Biotechnology, Inc., Dallas, TX, 
USA) and the nucleus was stained with DAPI. The fixed cells 
were observed by swept field confocal microscopy (SFCM; 
Prairie Technology, Middleton, WI, USA). 
mRNA transfection to cardiac fibroblasts
Cardiac fibroblasts (5×104 cells per well) were seeded in a 
24-well plate 1 day before transfection. eGFP mRNA (0.5 µg) 
was added to 50 µL of OptiMEM in a 1.5 mL Eppendorf tube. 
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The calculated amount of CRPPR-R9 (0.95 µg, 3.8 µg, 
and 9.5 µg resulting in 5, 20, and 50 molar charge ratio) or 
scramble sequence CRRPP-R9 (3.8 µg, 20 molar charge ratio) 
was added to the eGFP mRNA solution, and was incubated at 
room temperature for 15 minutes. Next, 1 µL of lipofectamine 
2000 in 50 µL OptiMEM was added to the solution and further 
incubated for 15 minutes. We describe sequential addition of 
CRPPR-R9 and lipofectamine, but simultaneous mixing of 
all three components is also a viable approach. After washing 
cells with warm PBS, the prepared eGFP mRNA complexes 
(100 µL) were transfected to the cells in 500 µL OptiMEM. 
The control cells were treated with only OptiMEM buffer 
or lipofectamine without peptides in the same ratio of lipo-
fectamine to eGFP mRNA. Only CRPPR-R9 cells were treated 
with eGFP mRNA (0.5 µg) and CRPPR-R9 (3.8 µg) mixture. 
The cells were incubated overnight and washed with PBS, 
followed by the addition of fresh growth media. At 24 hours 
post-transfection, fluorescence microscopic observations 
and flow cytometry analyses were conducted. Transfection 
efficiency was quantified based on the percentage of eGFP+ 
cardiac fibroblasts and mean eGFP fluorescence intensity of 
individual cells from the whole cell population after transfec-
tion was quantified by InCyte software (EMD Millipore).
Transfection efficiency and cytotoxicity 
optimization of crPPr-r9/lipofectamine 
transfection
Cardiac fibroblasts (5×104 cells/well) were seeded in a 24-well 
plate 1 day prior to transfection. Gata4 mRNA (0.5 µg per well) 
was mixed with lipofectamine (1 µL per well) or C-Lipo (3.8 
µg of CRPPR-R9 and 0.25 µL of lipofectamine per well), and 
was transfected for 4 hours in OptiMEM and further incubated 
in growth DMEM media for 20 hours. The same transfection 
was conducted daily for 1 week. On days 4, 7, and 14 of 
transfection, cells were washed with PBS and cell viability 
was measured with Cell Counting Kit-8. Cell viability was 
quantified with absorbance at 450 nm and normalized by the 
cell viability of the control cells without transfection. For trans-
fection efficiency and mean eGFP expression analysis, trans-
fection with the same formulation as described earlier, was 
conducted overnight and washed with PBS, followed by the 
addition of fresh growth media. At 24 hours post-transfection, 
flow cytometry analyses were conducted.
construction of in vitro transcription 
templates
The oligonucleotide sequences of Mef2c and Tbx5 were pro-
cured from pMX vectors as previously reported.2 A pcMV6 
vector containing Gata4 (MG227022) was purchased from 
Origene Technologies, Inc. (Rockville, MD, USA). BamHI 
and NotI restriction enzymes were used to cut Mef2c and 
Tbx5 genes from the pMX vector, and the Gata4 pcMV6 
vector was digested with BamHI and XhoI. The resulting 
digested genes were cloned in pcDNA™6/V5-His B, ligated 
with T4 DNA ligase (New England Biolabs), and then trans-
formed into DH5α by heat-shock treatments. Each GMT 
pcDNA plasmid was isolated by Plasmid Midi Kit (Qiagen 
NV) following the manufacturer’s manual. 
Synthesis of modified mRNAs
Modified mRNAs that are made of bases with modification 
for efficient translation and stability were synthesized with 
the MEGAscript T7 transcription kit (Life Technologies, 
Grand Island, NY). Individual GMT pcDNA plasmids were 
linearized by adding XhoI restriction enzyme and incubating 
for 1 hour at 37°C. The resulting linearized plasmids were 
then purified with QIAquick spin columns (Qiagen NV). Four 
micrograms of purified linear plasmids for each 40 µL reac-
tion were prepared. Adenosine triphosphate and guanosine 
triphosphate from the kit were used. The modified bases, 3′-0-
Me-m7G(5′)ppp(5′)G ARCA cap analog, 5-methylcytidine 
triphosphate, and pseudouridine triphosphate (TriLink Bio-
technologies, San Diego, CA, USA), were also mixed with 
the two triphosphates from the kit. Final nucleotide reaction 
concentrations were 6 mM for the cap analog, 1.5 mM for 
guanosine triphosphate, and 7.5 mM for the other nucleotides. 
mRNA synthesis mixtures were incubated for 6 hours at 
37°C, followed by Turbo DNase treatment for 30 minutes. 
Poly(A) tailing (Life Technologies) was conducted. Antarctic 
phosphatase (New England Biolabs) was added and the mix-
ture was incubated for 30 minutes at 37°C to remove residual 
5′-triphosphates. RNA was purified with MEGAclear spin 
columns as described in the manufacturer’s manual. RNA 
reprogramming cocktails were prepared by pooling individual 
RNA stocks with the ratio suitable for each experiment and 
a 100 ng/µL blend was prepared and frozen at -80°C until 
transfections were conducted.
Direct cardiac reprogramming using gMT 
mrNa transfection via c-lipo
Cardiac fibroblasts (3×105 cells/well) were prepared in 
gelatin-coated six-well plates and grown until cell density 
reached 70% confluency. Growth media was removed and 
the cells were PBS washed before transfection. GMT mRNA 
(1.2 µg) and CRPPR-R9 (9.12 µg) were mixed in 50 µL of 
OptiMEM for 10 minutes at room temperature. Lipofectamine 
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(0.6 µL in 50 µL of OptiMEM) was added to the complex and 
incubated for an additional 15 minutes at room temperature. 
Transfection mix in 700 µL of OptiMEM was added to cells 
and incubated for 4 hours. The cells were washed with PBS 
and further incubated in growth media. Daily transfections 
were conducted for 14 consecutive days and cell morphology 
was monitored. α-MHC-GFP-transfected cardiac fibroblasts 
were observed with fluorescence microscopy on day 7 and 
images were taken and processed with QCapture Pro 6 
(QImaging, Surrey, BC, Canada). GFP+ population percent-
age was quantified using flow cytometry and InCyte software 
at day 14 of transfection.
Immunohistochemistry staining for 
sarcomeric protein, α-actinin
After 14 times of daily transfection of neonatal cardiac fibro-
blasts without α-MHC-GFP reporter, the culture medium was 
removed and cells were washed with PBS three times. Induced 
cardiomyocytes were fixed in 4% paraformaldehyde (Santa 
Cruz Biotechnology, Inc.). After washing, blocking buffer 
containing 5% goat serum was given for 30 minutes at room 
temperature. α-actinin primary antibody (sc-15335; Santa 
Cruz Biotechnology, Inc.) was diluted 1:200 in blocking buf-
fer and incubated overnight at 4°C. After washing, secondary 
goat anti-rabbit IgG-CFL 488 antibody (sc-362262; Santa 
Cruz Biotechnology, Inc.) was added and incubated for 1 hour 
at room temperature. After nucleus staining with DAPI, the 
stained cells were observed by SFCM (Prairie Technology). 
cardiomyocyte marker gene expression 
analysis 
After 14 times of daily transfection, the transfected cells were 
cultured an additional 4 days from the last transfection in a 
cardiomyocyte medium. On day 18 from the initial transfec-
tion, total cells were lysed and mRNAs were extracted using 
Aurum Total RNA Mini Kit (Bio-rad Laboratories Inc.). 
cDNAs were prepared via iScript cDNA synthesis kit (Bio-
rad Laboratories Inc.) and real-time polymerase chain reac-
tion (RT-PCR) reactions were per formed with SsoAdvanced 
Universal SYBR Green Supermix (Bio-rad Laboratories 
Inc.). Primers are listed in Table S1. CFX Real-Time PCR 
system (Bio-Rad Laboratories Inc.) was used and data were 
analyzed by iQ5 software (Bio-Rad Laboratories Inc.). 
GAPDH was used for loading control and normalization.
stoichiometric analysis
Different ratios of the Gata4, Mef2c, and Tbx5 mRNAs were 
used: an equal ratio of GMT mRNAs (1:1:1), a three-fold 
excess of Gata4 to Mef2c and Tbx5 (3:1:1), and a three-fold 
excess of Tbx5 to Gata4 and Mef2c (1:1:3). The total mRNA 
amount was 1.2 µg for all samples and the same transfection 
method as described above was conducted. After 10 times 
of daily transfection, the transfected cells were cultured an 
additional 4 days from the last transfection. On day 14 from 
the initial transfection, mRNA was extracted and qRT-PCR 
was conducted as described previously.
statistical analysis
P-values were determined by Student’s t-test and one-way 
ANOVA using GraphPad Prism (GraphPad Software, Inc., 
La Jolla, CA, USA). P-values of less than 0.05 and 0.01 are 
indicated as * and **, respectively. 
Results and discussion
conventional transfection reagents 
are not effective or are toxic to cardiac 
fibroblasts
mRNA transfection to primary cardiac cells such as cardiac 
fibroblasts has been challenging.15,16 We tested seven differ-
ent transfection reagents on cardiac fibroblasts with eGFP 
mRNA, and all of the reagents had very low transfection effi-
ciency, except for lipofectamine 2000 (described henceforth 
as lipofectamine) which had a 20% transfection efficiency 
(Figure S1). However, lipofectamine caused severe cell dam-
age after 1 week of daily transfection, which is too short a 
period to induce direct cardiac reprogramming. Therefore, we 
designed a peptide-assisted transfection system that targets 
cardiac cells to improve the mRNA transfection efficiency 
of lipofectamine and also lower its cytotoxicity.
crPPr-r9 enhances the uptake of mrNa 
in cardiac fibroblasts
Peptide-assisted mRNA transfection is a promising way to 
overcome the intrinsic nature of lipofectamine that causes 
low efficiency and high toxicity to primary cells. We 
hypothesized that peptide targeting with CRPPR-R9 would 
improve the cardiac fibroblast transfection efficiency of 
lipofectamine by enhancing endocytosis, and would enable 
direct cardiac reprogramming with mRNAs. We investigated 
if CRPPR-R9 could enhance the uptake of Alexa594-labeled 
eGFP mRNA. CRPPR-R9 was complexed with Alexa594-
labeled eGFP mRNA at a molar charge ratio of 20:1. The 
formation of the CRPPR-R9/mRNA complex was confirmed 
with an electrophoretic mobility shift assay (Figure S2). The 
CRPPR-R9/mRNA complex was incubated with cardiac 
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fibroblasts for 30 minutes, and analyzed by fluorescence 
microscopy. Figure 2A demonstrates that the CRPPR-R9/
mRNA complex is robustly internalized, while cardiac fibro-
blasts treated with Alexa594-labeled mRNA alone exhibited 
minimal fluorescence. 
crPPr-r9 enhances the mrNa 
transfection efficiency of lipofectamine 
To investigate if CRPPR-R9 can form complexes with 
mRNA and lipofectamine, the CRPPR-R9/eGFP mRNA 
complex was mixed with lipofectamine. The complexes 
Figure 2 CRPPR-R9 facilitates mRNA delivery in cardiac fibroblasts and CRPPR-R9/lipofectamine improves mRNA transfection efficiency.
Notes: (A) Confocal images of cardiac fibroblasts treated with Alexa594-labeled mRNA/CRPPR-R9 complexes. mRNA and mRNA/CRPPR-R9 complexes were transfected 
into cardiac fibroblasts for 30 minutes. CRPPR-R9 induces facilitated mRNA uptake in cardiac fibroblasts. Alexa594-labeled mRNA and nucleus are shown in yellow and blue, 
respectively. Scale bar is 10 µm. (B) Transfection efficiency of eGFP mRNA on cardiac fibroblasts transfected by various combinations of CRPPR-R9 and lipofectamine and 
quantified by flow cytometry. CRPPR-R9 with lipofectamine increases eGFP mRNA transfection efficiency. (C) Mean eGFP fluorescence of cardiac fibroblasts quantified by 
flow cytometry. Mean eGFP fluorescence increases as transfection efficiency increases in CRPPR-R9 and lipofectamine transfection. The results represent the mean ± se, 
n=4. *P0.05; **P0.01. (D) Images of eGFP fluorescence in cardiac fibroblasts with eGFP mRNA. Scale bar is 10 µm.
Abbreviations: eGFP, enhanced green fluorescence protein; SE, standard error.
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formed from CRPPR-R9/mRNA/lipofectamine were 
centrifuged, isolated, and analyzed by gel electrophoresis 
for the presence of CRPPR-R9 and mRNA. Figure S3 shows 
the presence of CRPPR-R9 in the CRPPR-R9/mRNA/
lipofectamine complex. We investigated if CRPPR-R9 
can improve the mRNA transfection efficiency of lipo-
fectamine on cardiac fibroblasts. The CRPPR-R9/mRNA/
lipofectamine complex was treated to cardiac fibroblasts, 
and eGFP expression was determined by flow cytometry 
and fluorescence microscopy. Figure 2B demonstrates that 
CRPPR-R9/lipofectamine dramatically increases the eGFP 
mRNA transfection efficiency of lipofectamine. For example, 
CRPPR-R9/lipofectamine (charge ratio of 20) had an mRNA 
transfection efficiency of 44%, which was about two-fold 
higher than lipofectamine alone. In addition, the mean eGFP 
fluorescence in the CRPPR-R9/lipofectamine-transfected 
cardiac fibroblast cell was also increased by about two-fold 
in comparison to lipofectamine (Figure 2C). CRRPP-R9, 
a scrambled sequence with the same charge profiles as 
CRPPR-R9, was mixed with eGFP mRNA and lipofectamine 
(1:20), and eGFP expression in cardiac fibroblasts showed no 
improvement compared to lipofectamine alone. The results 
suggest that the enhanced transfection is due to the CRPPR 
sequence–specific interaction. Figure 2D shows fluorescence 
images of transfected cardiac fibroblasts that demonstrate 
improved lipofectamine transfection via CRPPR-R9. Addi-
tional transfection experiments in HeLa cells, a cervical 
cancer cell-line, show that CRPPR-R9 does not improve, and 
instead hampers, the transfection efficiency of lipofectamine 
in HeLa cells (Figure S4). Moreover, CRPPR-R9 alone had 
no toxicity to cardiac fibroblasts under these transfection 
conditions (Figure S5). 
CRPPR-R9 allows comparable levels 
of lipofectamine transfection with 
low toxicity
A key challenge in direct reprogramming with mRNA is the 
need for consecutive transfections for weeks. Transfection 
reagents such as lipofectamine generate significant toxicity 
if used repeatedly. Therefore, we investigated if C-Lipo with 
75% less lipofectamine (0.5 µL of lipofectamine with 7 µg 
of CRPPR-R9 peptide per 1 µg of mRNA) could transfect 
cells consecutively for 2 weeks with minimal toxicity by 
reducing the amount of lipofectamine given to the cells. 
Cardiac fibroblasts were treated with mRNA and either 
lipofectamine (Lipo, 2 µL lipofectamine per 1 µg mRNA) 
or C-Lipo, using 25% as much lipofectamine, daily for 
1 week; the cell viability and transfection efficiency were 
measured. Figure 3A demonstrates that C-Lipo has lower 
toxicity than Lipo. C-Lipo caused a 25% cell viability drop 
after 1 week of transfection, whereas Lipo caused a 90% cell 
viability drop, and the viability difference between the two 
transfection reagents became more significant in week 2. The 
higher cell viability of C-Lipo transfection in comparison to 
lipofectamine is mainly due to the reduced amount of lipo-
fectamine (Figure S6). In addition, C-Lipo had a transfection 
efficiency that was similar to Lipo and had a higher mean 
eGFP expression level per cell (Figures 3B and C). These 
results show that C-Lipo can efficiently transfect cardiac 
fibroblasts with low cytotoxicity. 
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Figure 3 C-Lipo with reduced lipofectamine amount transfects cardiac fibroblasts efficiently without significant toxicity.
Notes: (A) Cell viability of C-Lipo (0.5 µl of lipofectamine with 7 µg of crPPr-r9 peptide per 1 µg mRNA) after daily transfections. Cardiac fibroblasts were transfected 
with C-Lipo and Lipo daily for 1 week and cell viabilities were measured on days 4 and 7. C-Lipo allows mRNA transfection in cardiac fibroblasts without significant toxicity 
for 1 week compared to Lipo, which causes significant toxicity. (B) and (C) Flow cytometry analyses of cardiac fibroblasts treated with C-Lipo and Lipo. C-Lipo shows 
comparable levels of transfection efficiency and higher mean eGFP fluorescence compared to Lipo. The results represent the mean ± se, n=5. *P0.05; **P0.01.
Abbreviations: eGFP, enhanced green fluorescence protein; SE, standard error; ns, not significant.
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gFP expression in α-MHC-gFP cardiac 
fibroblasts after GMT mRNA transfection 
via c-lipo
We investigated if transfection of GMT mRNAs with C-Lipo 
could induce the expression of α-MHC, a cardiomyocyte 
marker gene, from cardiac fibroblasts. Cardiac fibroblasts 
that have the GFP gene driven by the α-MHC promoter were 
isolated from neonatal transgenic mice. Fresh α-MHC-GFP 
cardiac fibroblasts were transfected with GMT mRNAs via 
C-Lipo every day for 7 days. Figure 4A demonstrates that 
GMT mRNA transfection with C-Lipo does induce α-MHC 
expression in 0.5% of transfected cardiac fibroblasts. 
GFP expression from GMT mRNA–transfected cardiac 
fibroblasts was less compared to the reported result of ret-
roviral transduction (17%).2,3 GFP+ cells first appeared at 
day 7 from the initial transfection. GFP+ cells consistently 
expressed GFP for 20 days of culture until we discontinued 
observation. 
?????????????????
α?????????
?
? ?
????????????????×
??× ??×
??×?
Figure 4 Transfection of GMT mRNAs on cardiac fibroblasts induces expression of cardiomyocyte marker genes and striated cardiac muscle structure.
Notes: (A) Fluorescence images of α-MHC promoter-driven GFP expression from GMT mRNA transfected cardiac fibroblasts. α-MHC-GFP cardiac fibroblasts were 
transfected daily with GMT mRNAs for 7 days and observed with fluorescence microscope. (a, b) Both bright field and green fluorescence images were taken with 10× 
magnification. (c, d) 20× magnification images were taken from two additional regions. Scale bar is 10 µm. (B) Immunohistochemistry staining of α-actinin in gMT mrNa/c-
Lipo transfected cardiac fibroblasts. Inducted cardiomyocyte-like cells express α-actinin and have striated cardiac muscle structure. Scale bar is 2 µm.
Abbreviations: GFP, green fluorescence protein; GMT, Gata4, Mef2c, and Tbx5.
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Figure 5 Transfection of gMT mrNas via c-lipo induces expression of cardiomyocyte 
marker genes from transfected cardiac fibroblasts.
Notes: Quantification of the relative expression of cardiomyocyte marker genes 
after 2 weeks of transfection. gMT mrNa transfection via c-lipo drives cardiac 
fibroblasts to express cardiomyocyte marker genes: Actc1, Actn2, Gja1, Hand2, and 
Tnnt2. The results represent the mean ± se, n=3. *P0.05; **P0.01.
Abbreviations: GMT, Gata4, Mef2c, and Tbx5; SE, standard error.
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cardiomyocyte marker genes are 
upregulated in cardiac fibroblasts 
transfected with gMT mrNa via c-lipo
We investigated if transfection of cardiac fibroblasts 
for 14 days with GMT mRNA/C-Lipo could induce the 
characteristics of cardiomyocytes using immunostaining 
and RT-PCR. Figure 4B demonstrates that α-actinin is 
expressed in the induced cardiomyocyte-like cells after 
GMT mRNA/C-Lipo transfection and striated muscle 
structure is observed with α-actinin staining.20 Addition-
ally, Figure 5 demonstrates that 14 days of transfection 
with GMT mRNA/C-Lipo induced a significant increase 
in the levels of many cardiomyocyte marker genes. For 
example, the cardiomyocyte marker genes that are important 
in cardiomyocyte development and function: Actc1, Actn2, 
Gja1, Hand2, and Tnnt2, were significantly upregulated in 
comparison to their levels in the control cardiac fibroblasts 
without transfections. These results further demonstrate that 
the transfection of GMT mRNA/C-Lipo induces cardio-
myocyte marker genes from cardiac fibroblasts, suggesting 
direct reprogramming towards the cardiomyocyte lineage. 
The expression profile of the marker genes in the cells 
transfected with only lipofectamine was unavailable for 
further studies due to significant cell death after transfec-
tion for 1 week. The results of α-MHC-GFP expression, 
striated cardiac structure from α-actinin staining, and car-
diomyocyte marker gene overexpression collectively sup-
port the initiation of direct cardiac reprogramming toward 
cardiomyocyte-like cells.
stoichiometric ratio of gMT mrNas 
affects the expression pattern of induced 
cardiomyocyte-like cells
mRNA transfection for direct reprogramming has the 
advantage of precisely controlling the stoichiometry of 
reprogramming factors. Understanding the optimal stoichio-
metric ratio of reprogramming factors is a key step toward 
addressing the significant challenges of improving the 
reprogramming efficiency and maturity of reprogrammed 
cells.21 In order to understand how the ratio of reprogram-
ming factors affects the direct reprogramming process, a 
stoichiometric study was conducted with three ratios of 
mRNAs: equal molar ratio of Gata4, Mef2c, and Tbx5 
(1:1:1), three-fold molar excess of Gata4 to Mef2c and 
Tbx5 (3:1:1), and three-fold molar excess of Tbx5 to Gata4 
and Mef2c (1:1:3). The ratios of reprogramming factors 
were decided based on the human induced pluripotent stem 
(hiPS) cell result that reprogramming was efficient when 
the Oct4 gene was expressed three times more than other 
reprogramming factors.22 Figure 6 demonstrates that stoi-
chiometry plays a major role in controlling cardiomyocyte 
marker gene expression patterns. For example, excess Tbx5 
(1:1:3) induced higher expression of Gja1 and Hand2, and 
excess Gata4 (3:1:1) increased the expression of Nppa and 
Tnnt2. High levels of Nppa expression were observed in 
cells transfected with excess Gata4 mRNA (3:1:1), which 
can be explained by a direct transcriptional regulation of 
Nppa by Gata4.23 Also, the fact that excess Tbx5 mRNA 
(1:1:3) induces the overexpression of Gja1, a gap junction 
alpha-1 protein, which is a key player in the synchro-
nized contraction of the heart, implies the importance of 
Tbx5 in functionality of induced cardiomyocytes.24 Our 
stoichiometric study demonstrated that the expression of 
cardiomyocyte marker genes is dependent on the ratio of 
GMT mRNAs. This is the first demonstration of the effect 
of stoichiometry of reprogramming factors in direct cardiac 
reprogramming to the best of our knowledge. mRNA has an 
advantage of precise control on stoichiometry and mRNA 
stoichiometric studies have a high potential to improve 
the efficiency of direct reprogramming and the functionality 
of induced cardiomyocytes. 
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Figure 6 Stoichiometric ratio of GMT mRNAs influences cardiomyocyte marker gene expression patterns.
Notes: Quantification of the relative expression of cardiomyocyte marker genes in cardiac fibroblasts transfected with various stoichiometric ratios of GMT mRNAs. Gene 
expression levels of Actc1, Actn2, Gja1, Hand2, Nppa, and Tnnt2 were affected by the stoichiometric ratio of GMT mRNAs. The results represent the mean ± se, n=3. *P0.05; 
**P0.01; statistical significance was tested between the control and each sample.
Abbreviations: GMT, Gata4, Mef2c, and Tbx5; SE, standard error.
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Conclusion
In this study, we present a peptide-assisted mRNA transfec-
tion method that can induce the direct reprogramming of 
cultured mouse cardiac fibroblasts towards cardiomyocyte-
like cells with moderate efficiency. The C-Lipo significantly 
reduces cytotoxicity and improves cell viability during mul-
tiple mRNA transfections, in comparison to lipofectamine 
transfection. GMT mRNA transfection via C-Lipo induced 
significant overexpression of cardiomyocyte marker genes in 
cultured mouse cardiac fibroblasts. This study demonstrates 
that mRNA can be utilized for direct cardiac reprogramming 
and is useful for stoichiometric control of reprogramming 
factors. Furthermore, our research may provide groundwork 
for the development of in vivo mRNA delivery vehicles to 
the infarcted heart.
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Supplementary materials
Figure S1 egFP mrNa transfection was optimized with various transfection reagents. 
Notes: Various ratios of eGFP mRNA and transfection reagents were tested for cardiac fibroblast transfection. Compared to mouse embryonic fibroblasts that are easy to 
transfect with lipofectamine, cardiac fibroblasts show inefficient transfection in tested conditions. Among the tested transfection reagents, lipofectamine (1 µg mrNa to 2 µl 
lipofectamine) shows the best transfection efficiency. Fluorescence images were taken from a confluent 24-well plate. Scale of width of each image is 50 µm. Fluorescence 
images of transfection reagents that had very inefficient transfection including TransIT-X2, TransIT-mRNA (Mirus Bio LLC, Madison, WI, USA), bPEI, and PEG-polylysine 
(22 ethylene glycol units, 50 lysine units) are not shown. Transfection was conducted as described in the main text.
Abbreviations: bPEI, branched polyethyleneimine; eGFP, enhanced green fluorescence protein.
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Figure S2 Electrophoretic mobility shift assay shows complexation of mRNA and CRPPR-R9.
Notes: EMSA was conducted to investigate if CRPPR-R9 complexes with mRNA. A mixture of CRPPR-R9 and mRNA produced visible retarded RNA bands from a molar 
charge ratio of one ([positive amines in peptide] to [phosphates in mRNA]) and a complete complexation was observed in a molar charge ratio of 4 or above. Unbound 
mRNA bands look smeared because different sizes of polyA tail (10–1,000 bp) were added to eGFP mRNA during polyA tailing. 
Abbreviations: bp, base pairs; eGFP, enhanced green fluorescence protein; EMSA, electrophoretic mobility shift assay.
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Figure S3 gel electrophoresis after third wash step shows crPPr-r9 incorporation 
in c-lipo.
Notes: To study whether the crPPr-r9 peptide forms a complex together with 
mrNa and lipofectamine, c-lipo formation and gel electrophoresis were conducted. 
C-Lipo was formulated as described in the manuscript, centrifuged at 14,000× g for 
30 minutes, and the supernatant containing unbound CRPPR-R9 was removed. PBS 
(1 ml) was added to the solution, centrifugation repeated, and the supernatant 
removed. This wash step was conducted twice. During the third wash step, the 
pellet was redispersed with 20 µl PBs, centrifuged, and the solution was carefully 
collected into pellet and supernatant for gel electrophoresis. The supernatant of 
the wash, liposome pellet, and positive control were analyzed with sDs-Page gel 
electrophoresis. The gel was stained with sYBr green and coomassie Blue. The 
third wash solution did not stain any mrNa or crPPr, showing that the wash steps 
were properly conducted. Positive control of the mrNa and crPPr peptide shows 
that c-lipo contains mrNa and crPPr peptide. Moreover, unlike the supernatant 
of the centrifuged C-Lipo that could not transfect cardiac fibroblasts, pelleted C-Lipo 
transfected cardiac fibroblasts and generated eGFP. The results prove that the CRPPR 
peptide is associated in c-lipo. scale of width of each image is 50 µm.
Abbreviations: eGFP, enhanced green fluorescence protein; PBS, phosphate buf-
fered saline; sDs-Page, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
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Figure S4 eGFP transfection efficiency shows that the CRPPR-R9 peptide does not 
improve lipofectamine transfection in hela cells, cervical carcinoma cells, which are 
not from cardiac origin.
Notes: eGFP mRNA transfection in HeLa cells was analyzed by flow cytometry. 
eGFP mRNA transfection efficiency of lipofectamine, CRPPR-R9/Lipo, and CRRPP-
R9(scramble)/Lipo are shown. Both CRRPP-R9 and CRPPR-R9 transfection 
with lipofectamine show even lower transfection efficiencies compared to the 
lipofectamine only transfection. The results suggest that the crPPr-r9 peptide is 
not effective in HeLa cells that are not targeted by the CRPPR peptide sequence. 
We speculate that the very low transfection efficiency of peptide/lipofectamine in 
HeLa cells is due to a charge imbalance that interferes with the complexation of 
lipofectamine and mrNas. The results represent mean ± se, n=3. crPPr-r9 or 
crrPP-r9 (3.8 µg, 20 molar charge ratio) was added to the egFP mrNa (0.5 µg), 
and incubated at room temperature for 15 minutes. Next, 1 µl of lipofectamine 
2000 in 50 µL OptiMEM was added to the solution and further incubated for 
15 minutes. Cardiac fibroblasts were transfected overnight as described earlier. 
At 24 hours post-transfection, flow cytometry analysis was conducted. Transfection 
efficiency was quantified based on the percentage of eGFP+ cardiac fibroblasts using 
Incyte software (eMD Millipore, Billerica, Ma, Usa).
Abbreviations: eGFP, enhanced green fluorescence protein; SE, standard error.
Figure S5 CRPPR-R9 does not affect cardiac fibroblast viability. 
Notes: The cell viability of cardiac fibroblasts at various concentrations of CRPPR-
r9 was measured with ccK-8. crPPr-r9 and lipofectamine concentrations were 
determined based on transfection conditions (CRPPR 1× =3.8 µg of crPPr-r9 
per well of a 24-well plate; lipo 5× =5 µl per well of a 24-well plate). The result 
shows that CRPPR-R9 does not compromise cell viability even at five-fold higher 
concentration than the concentration used for transfection, whereas a similar 
concentration level of lipofectamine caused significant cell death in 4 days.
Abbreviation: ccK-8, cell counting Kit-8.
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Figure S6 low cytotoxicity of c-lipo transfection is due to the reduced amount 
of lipofectamine. 
Notes: Cell viability of transfected cardiac fibroblasts was measured on day 14 from the 
initial single transfection. Transfection was conducted with GMT mRNAs as described 
in the main manuscript. One-quarter of the lipo sample contained one-quarter of the 
lipofectamine amount used for lipo. The c-lipo and 1/4 lipo transfections showed 
similar levels of cell viability. This result suggests that the high cell viability of the 
c-lipo transfection is mainly due to the reduced amount of lipofectamine.
Abbreviation: GMT, Gata4, Mef2c, and Tbx5.
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Table S1 Primer list
Actc1 Forward TTTgcggaTaTcgaTgTcacacTTc
reverse acTgTgTTacgTcgcccTggaT
Actn2 Forward aggggaTTgTgcgccgaaTc
reverse agcTaacagaaTaTgTaaggT
Gja1 Forward agcagcagacTTTgaaacTTTaaa
reverse ccgacagccacaccTTcccT
Hand2 Forward gacgTgaaagaggagaaga
reverse gTgcTgTggccagccTgTccgg
Nppa Forward aaccagagTgggcagagacag
reverse TgTgTTggacaccgcacTgTa
Tnnt2 Forward gTgTgcagTcccTgTTcaga
reverse gcTTgggTTTggTgTccTcT
